Young patients with lung cancer may also be more likely to have underlying germline or hereditary TP53 mutations from syndromes such as Li-Fraumeni Syndrome (82), though it is unclear if germline TP53 mutation confers an increased risk of treatment resistance in this context (13). The gene discussed is TP53; the disease is Li-Fraumeni syndrome.